N/A
Completed N=400
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Prostatic Hyperplasia
Source: ClinicalTrials.gov NCT01390870 ↗
Enrolled (actual)
400
Serious AEs
—
Results posted
Mar 2012
Primary outcomePrimary: Number of Participants Reporting Compliance With Medication — 239; 161 participants
Summary
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged prostate (EP). Adherence with EP therapy will be evaluated. The researchers believe that the majority of participants will report that they are compliant with therapy. The data source is a cross-sectional patient survey administered at one time point.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Reporting Compliance With Medication |
239; 161 | — |
Eligibility Criteria
Inclusion Criteria
- Males
- Aged 50 years or older
- Residents of the United States
- Receiving a prescription for an enlarged prostate (EP) treatment within 12 months prior to survey initiation
Exclusion Criteria
- Patients with prostate cancer
- no health/prescription insurance
- patients receiving medication(s) for EP on a PRN basis
Data sourced from ClinicalTrials.gov (NCT01390870). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.